Can the Administration of Antithrombin III Decrease the Risk of Cerebral Hemorrhagein Premature Infants?Fulia F.a · Cordaro S.a · Meo P.a · Gitto P.a · Gitto E.a · Trimarchi G.b · Adelardi S.a · Barberi I.a
aNeonatal Intensive Care Unit, Department of Pediatrics, and bInstitute of Statistics, University of Messina, Italy Biol Neonate 2003;83:1–5 (DOI:10.1159/000067005)
This study was carried out to determine whether the administration of antithrombin III decreases the risk of intraventricular hemorrhage in premature infants. In a randomized study, 60 infants born before 30 weeks of gestation were assigned to receive a loading dose of antithrombin III or placebo. There was no significant difference in the incidence of intraventricular hemorrhage between the antithrombin III and the placebo group (27.5 vs. 32%). Partial thromboplastin time, Quick’s prothrombin time and platelet count were also not significantly different between the 2 groups. We conclude that the administration of antithrombin III during the first 2 days of life does not decrease incidence of intraventricular hemorrhage. Antithrombin III is a very expensive therapy and its benefits should be carefully investigated before being recommended as valuable therapy.
|Direct payment||This item at the regular price: USD 38.00|
|Payment from account||With a Karger Pay-per-View account (down payment USD 150)
you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50